TheÀ216G/T, À191C/A, intron 1 and Arg497Lys epidermal growth factor receptor (EGFR) polymorphisms were evaluated in 92 advanced non-smallcell lung cancer patients treated with gefitinib, an EGFR tyrosine-kinase inhibitor. Improved progression free survival (PFS) was found in patients homozygous for the shorter lengths of intron 1 polymorphism (S/S; S ¼ 16 or fewer CA repeats; log-rank test (LRT) P ¼ 0.03) and for patients carrying any T allele of the À216G/T polymorphism (LRT, P ¼ 0.005). When considered together, patients with intron 1 S/S genotype and at least one T allele of À216G/T had improved PFS (LRT P ¼ 0.0006; adjusted hazard ratio (AHR), 0.60 (95% confidence interval, 0.36-0.98)) and overall survival (LRT P ¼ 0.02; AHR, 0.60 (0.36-1.00)) when compared with all others. The T allele of À216G/T was also associated with significantly higher rates of stable disease/partial response (P ¼ 0.01) and a significantly higher risk of treatment-related rash/diarrhea (P ¼ 0.004, multivariate model). EGFR intron 1 and -216G/T polymorphisms influence clinical outcomes in gefitinibtreated non-small-cell lung cancer patients.
Introduction
The human epidermal growth factor receptor (EGFR) is a 170 kDa transmembrane glycoprotein with an intracellular tyrosine protein kinase domain that plays critical cellular signaling roles in diverse pathways involved in cellular proliferation, apoptosis, angiogenesis and metastasis. 1 Binding of various activating ligands trigger the formation of EGFR homodimer and heterodimer complexes, resulting in tyrosine kinase phosphorylation and activation of a number of intracellular signaling pathways. Although EGFR is expressed in a majority of non-small-cell lung cancers (NSCLC), EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib produce clinical responses in a small subset of patients. 2 EGFR activating mutations clustered around the ATP-binding pocket of the tyrosine kinase domain have been strongly associated with sensitivity to gefitinib. 3, 4 EGFR amplification has also been associated with response to gefitinib. [5] [6] [7] Neither amplification nor mutation fully explains the clinical response of NSCLC to EGFR tyrosine kinase inhibitors.
Located at 7p12.3-p.1, the EGFR gene has a number of polymorphic variants, and several are associated with alterations in gene expression. Liu et al. 8 evaluated EGFR single nucleotide polymorphisms (SNPs) in the promoter region using transient transfection in human cancer and primary cell lines. The T allele of the À216G/T polymorphism was associated with increased promoter activity mediated through its location within a Sp1 recognition site sequence. Both the À216G/T and À191C/A polymorphisms are located in the transcriptional start site region of the promoter where multiple nuclear affinity sites are located, clues to their potential impact in EGFR regulation. 8 One of the enhancer elements for EGFR is located in intron 1, and EGFR transcription may be prematurely terminated in intron 1.
9,10 A well-described dinucleotide CA repeat sequence polymorphism in intron 1 of EGFR ranges from 14 to 22 repeats, with the most common allele being 16 repeats. 11 The shorter (16 repeat) alleles are associated with greater EGFR expression compared with the longer repeats. 11, 12 This CA repeat modulated EGFR content in breast cancers in vivo. 13 This polymorphism mediated response to EGFR tyrosine kinase inhibitors in head and neck cancer cell lines, whereby the shorter number of repeats was associated with increased tumor inhibition by erlotinib.
14 Further, the number of repeats was identical between tumor and normal tissue DNA in head and neck squamous cell cancer patients, showing that germline evaluation of this polymorphism is representative of tumor tissue. 13 A non-synonymous exonic polymorphism at codon 497 in the extracellular domain of EGFR (producing an arginine-to-lysine substitution) was found to modulate the association between the intron 1 CA repeat polymorphism and pelvic recurrences in rectal cancer. 15 In other settings, genetic variations have shown promise as modulators of toxicity and chemotherapy treatment outcomes. [16] [17] [18] [19] However, the role of inherited genetic variations in modulating response in NSCLC to tyrosine kinase inhibitors, particularly in a clinical setting, has not been explored fully.
We evaluated the À191C/A, À216G/T, intron 1 CA repeat and Arg497Lys polymorphisms in 92 advanced stage (Stage IIIB/IV) NSCLC patients with good performance status (Eastern Cooperative Oncology Group (ECOG) 0-2) treated with gefitinib. We specifically hypothesized that combinations of À216G/T and intron 1 CA repeats associated with greater EGFR expression levels would result in improved sensitivity to the EGFR tyrosine kinase inhibitor, gefitinib, as measured by prolonged progression-free survival (PFS) and overall survival (OS).
Results

Patient and treatment characteristics
A total of 122 patients were enrolled in both the molecular epidemiologic study and one of the gefitinib treatment studies. Of these, we analyzed 92 patients with advanced Stage IIIB/IV NSCLC and good performance status (ECOG 0-2), all treated with gefitinib, who had complete outcomes and genotyping data. The strict criteria were designed to mirror standard criteria for entry into other clinical treatment studies. Reasons for exclusion included genotyping failure for at least one of the four polymorphisms (n ¼ 6), early stage diagnosis at the start of therapy (n ¼ 6), or poor performance status (ECOG 3-4; n ¼ 20). Two patients had both early disease and poor performance status. All seven patients who had been deemed to have a life expectancy of less than 12 weeks also had poor performance status.
Demographic data for the 92 patients are presented in Table 1 . The vast majority of patients were Caucasian, had Stage IV disease, had performance status of ECOG 1, were treated with gefitinib alone, and had previously received chemotherapy. The relatively higher proportions of females and never-smokers reflect the common oncologic practice of preferentially offering gefitinib therapy to these patient subsets.
Genotype information
For the intron 1 dinucleotide CA repeat polymorphism, the frequency of the allele with 16 CA repeats was 56%, followed by the allele with 20 CA repeats (18%). Frequency distributions were similar between our study and other Caucasianpredominant samples. 12, 21, 22 The most frequent genotype was homozygosity for the 16 CA repeat (n ¼ 32; 35%). There were 33 (36%) patients carrying only alleles with 16 CA or fewer repeats (i.e., intron 1 S/S genotype). For the À216G/T polymorphism, the genotype frequencies were 37% (G/G), 53% (G/T) and 10% (T/T). For the À191C/A polymorphism, the genotype frequencies were 88% (C/C), 11% (C/A) and 1% (A/A). For the Arg497Lys polymorphism, the genotype frequencies were 47% (Arg/Arg), 45% (Arg/Lys) and 9% (Lys/ Lys). D 0 for the À216G/T and À191C/A polymorphisms was 0.55, suggesting moderate linkage disequilibrium. All other D 0 comparisons were less than 0.15, suggesting little linkage disequilibrium among the other SNP pairs. Each of the three SNPs was in Hardy-Weinberg equilibrium (P40.10 for each comparison). Haplotype frequencies of the À216G/T and À191C/A polymorphisms were 57% (G-C), 36% (T-C) and 8% (G-A), similar to a published report. 8 There were no statistically significant relationships between genotype and each of the following clinical characteristics: age, gender, stage, performance status, smoking status, histology of cancer and concurrent or prior treatment with chemotherapy.
EGFR polymorphisms and skin and gastrointestinal treatment side effects Most of the skin and gastrointestinal treatment side effects were NCI toxicity scale Grade 0-2, similar to previous reports. 2 There were only two patients with Grade 3 rash, and three with Grade 3 diarrhea; no Grade 4 events were detected. Because presence of any grade of rash and presence of any grade of diarrhea were highly correlated (Fisher's exact test (FET), P ¼ 0.002), we defined the variable 'any toxicity' to mean the presence of any grade of either rash or diarrhea in our analyses. Neither rash, diarrhea, nor 'any toxicity' was associated with the intron 1 CA dinucleotide repeat polymorphism, the À191C/A, or Arg497Lys SNPs. EGFR polymorphisms and lung cancer survival
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However, the À216G/T promoter SNP was associated with diarrhea (FET, P ¼ 0.05) and with 'any toxicity' (FET, P ¼ 0.04). In the multivariate models, carrying the variant allele of the À216G/T promoter polymorphism was associated with a substantially increased risk of diarrhea (odds ratios (OR), 2.63; 95% confidence interval (CI), 1.12-6.17; P ¼ 0.03, where no other covariates were significant or adjusted for), or risk of 'any toxicity' (adjusted OR, 3.09; 95% CI, 1.42-6.71; P ¼ 0.004, adjusted for the only other significant variable, gender). Because of these strong correlations, the logistic regression and Cox proportional hazards models that evaluated the EGFR À216G/T SNP incorporated the variable, 'any grade of rash' instead of 'any toxicity' in the adjusted models.
EGFR polymorphisms and response rates Of the 92 patients evaluated, 7.6% (95% CI, 3-15%; n ¼ 7) of individuals had partial response (PR), 29% (95% CI, 20-40%; n ¼ 27) had stable disease (SD), and 63% (95% CI, 52-73%; n ¼ 58) had progressive disease (PD) in our sample, similar to published studies. 2 As shown in Table 1 , performance status, smoking status, prior chemotherapy, histology and presence of rash or 'any toxicity' were all associated with response rate, whereas gender and diarrhea were of borderline significance. After combining PR and SD together (i.e., comparing two-levels: non-progressors and those with PD), performance status (FET, P ¼ 0.08), smoking (FET, P ¼ 0.06), prior chemotherapy (FET, P ¼ 0.006), histology (FET, P ¼ 0.01), rash (FET, P ¼ 0.009), diarrhea (FET, P ¼ 0.07) and 'any toxicity' (FET, Po0.001) were associated with nonprogression univariately. Regardless of whether the response categories were considered separately (three-level) or combined into progressors and non-progressors (SD þ PR; twolevel), neither the intron 1 (FET: P ¼ 0.43, three-level and P ¼ 0.26, two-level), À191C/A (FET: P ¼ 1.0, three-level and two-level), nor Arg497Lys (FET: P ¼ 0.36, three-level and P ¼ 0.39, two-level) polymorphisms was associated with response rates. However, carrying a T allele of the À216G/T polymorphism was associated with increased response rate (FET, P ¼ 0.03, three-level, and P ¼ 0.01, two-level). The proportions of individuals carrying at least one T allele were 53% (PD; n ¼ 58), 82% (SD, n ¼ 27), and 71% (PR, n ¼ 7). Adjusted OR for disease progression for carrying at least one T allele of À216G/T (compared with the G/G genotype) was 0.40 (95% CI, 0.14-1.18), adjusting for prior chemotherapy, smoking status, and presence of any grade of rash (independent variables in the multivariate model).
PFS and OS analyses
Median PFS was 3.2. months and median OS 10.9 months. Median follow-up for PFS was 28.5 months; for OS, median follow-up was 29.9 months. There were 82 deaths (event rate of 89%), of which 77 occurred after disease progression. Of the deaths without disease progression, one patient died of suspected pulmonary embolism, two died unexpectedly of unknown causes, and two had clinical deterioration consistent with clinical progression without radiologic or pathologic confirmation. Four individuals were alive without disease progression at last contact, while six had progressed through gefitinib but were still alive at last contact. Important associations between clinical characteristics and PFS or OS are shown in Table 2 , and are similar to prognostic variables previously identified in association with gefitinib treatment. [2] [3] [4] 23, 24 For the intron 1 dinucleotide CA repeat polymorphism, carrying the S/S genotype was associated with improved PFS (Figure 1 ; Table 3 ), but there was no association with OS. For the À216G/T polymorphism, carrying at least one T allele was associated with improved PFS (Figure 2a ; Table 3 ), but there was no difference with OS. In the case of the À191C/A and Arg497Lys polymorphisms, there were no differences in PFS or OS observed (Table 3 ). All Cox proportional hazards models for PFS were adjusted for smoking status, 'any toxicity', histology, and prior chemotherapy treatments. All Cox proportional hazards models for OS were adjusted for gender, performance status, smoking status, 'any toxicity', and histology. These represented the most significant prognostic variables in this sample as determined by univariate analyses (see Table 2 ) and each was found to be an independent variable (set at P-value of 0.10 or less) in the multivariate analyses (not shown).
In addition to evaluating individual EGFR polymorphisms, patients with expected differences in EGFR expression as assigned by genotype combinations of the intron 1 dinucleotide CA repeat and À216G/T polymorphisms were compared. We defined lower expression level (LO-EGFR) as individuals who carried at least one long (L) allele of intron 1 and the G/G wild-type genotype of the À216G/T polymorphism (n ¼ 28). All other individuals were considered to have higher expression levels (HI-EGFR; n ¼ 64). This analysis, according to presumed EGFR expression level, revealed significant differences in both PFS and OS ( Figure  3a and b). Median PFS was 3.9 months (HI-EGFR) versus 2.0 months (LO-EGFR); log-rank P ¼ 0.0006. The adjusted hazard ratio (AHR) for HI-EGFR versus LO-EGFR was 0.60 (95% CI: 0.36-0.98) for PFS. Median OS was 7.6 months (LO-EGFR) versus 12.0 months (HI-EGFR); log-rank P ¼ 0.02. The AHR for HI-EGFR versus LO-EGFR was 0.60 (95% CI: 0.36-1.00) for OS.
In secondary analyses, we compared the most extreme groups (intron 1 S/S and at least one T allele of À216G/T (n ¼ 27) versus individuals with at least one L allele of intron 1 and G/G genotypes (n ¼ 28)) and found similarly significant results in both OS and PFS (data not shown). Evaluation of only the individuals enrolled in the Expanded Access Study (n ¼ 83) also showed consistent and similar results, as did analyses where the intron 1 polymorphism was dichotomized at 17 CA repeats rather than 16 CA repeats, as it is unclear whether the allele with 17 CA repeats produces gene expression that is more similar to 16 repeats or more similar to 18 or greater repeats.
We were concerned that the polymorphism results may reflect a generally better prognosis with the presence of the polymorphic variants as opposed to a pharmacogenetic response. To test this, a comparison group of 128 gefitinibuntreated patients were assessed for the À216G/T and intron 1 polymorphism. There were no differences in either OS or PFS (P40.2 by Kaplan-Meier method for all analyses) for the À216G/T and intron 1 polymorphism.
We also tried to assess the relationship between EGFR activating mutations, florescence in situ hybridization (FISH) and these polymorphic variants. Unfortunately, because the majority of patients had small, fine-needle aspiration biopsies, only eight of the 92 original patients were assessable for mutation status. No associations were found. Similarly, there was insufficient residual tissue to appropriately test EGFR FISH status after a pilot feasibility study was performed.
Discussion
We explored the relationship between EGFR genetic polymorphisms and the response to an EGFR tyrosine kinase inhibitor, gefitinib, in advanced stage NSCLC in a predomi- The 'À' can be either allele; thus, for À216G/A, T/À means T/T or T/G.
d L refers to alleles with 17 or greater dinucleotide CA repeats. S refers to alleles with 16 or fewer dinucleotide CA repeats. e The variable 'any toxicity' was substituted with 'any grade of rash' in the adjusted models because the À216G/T polymorphism was found to be highly correlated with both 'any toxicity' and any grade of diarrhea.
EGFR polymorphisms and lung cancer survival G Liu et al nantly Caucasian sample. The results show that patients homozygous for the shorter length alleles of the intron 1 dinucleotide CA repeat polymorphism or individuals carrying at least one T allele of the À216G/T promoter polymorphism are associated with improved PFS individually or when evaluated together. This combination of polymorphic variants was associated also with improved OS. We found a correlation between the T allele of the À216G/T polymorphism and development of any grade of treatment-related rash or diarrhea. When we evaluated two other previously described polymorphisms, neither the À191C/A promoter SNP nor the Arg497Lys SNP was known to alter EGFR gene expression, and neither was associated with treatment outcomes.
Although initial publications found no clear relationship between protein expression and clinical outcomes in patients treated with EGFR tyrosine-kinase inhibitors, 2, 23 others have found such an association. 5, 25 Recently, activating mutations 3, 4 and amplification of EGFR 5, 6 have been associated with increased mRNA expression and each has been highly correlated with clinical outcomes. Evidence has been growing that short alleles of the intron 1 CA dinucleotide repeat and the T allele of the À216G/T promoter SNP are also associated with increased mRNA levels of EGFR. 8, 11 Further, shorter repeat lengths of the intron 1 dinucleotide CA repeat have already been shown to correlate with improved response to gefitinib in head and neck cancer cell lines, and also in skin toxicity in head and neck cancer patients treated with an EGFR tyrosine kinase inhibitor.
14 Further, recent data also found associations between erlotinib toxicity and EGFR polymorphisms. Our results in NSCLC patients are consistent with these results.
Our results further support the concept that a number of disparate processes regulate EGFR gene expression. The relationships between EGFR mutation, amplification and genetic polymorphisms still require further study. Although still controversial, patients with EGFR mutation and EGFR amplification may represent distinct subsets of patients. [5] [6] [7] Associations have been described between the intron 1 polymorphism and EGFR amplification. 26 Because most of the patients in the current study were of advanced stage, many were diagnosed using fine-needle aspirates and small biopsies, and insufficient tissue was available for concurrent analysis of EGFR amplification and EGFR mutation.
Different EGFR regulatory processes may be dominant in different racial and genetic backgrounds. For instance, East Asians who have a larger number of CA dinucleotide repeats (which would suggest greater resistance to EGFR tyrosine kinase inhibitors) actually have a greater proportion of responders to EGFR tyrosine kinase inhibitors. 22, 23 In this setting, higher rates of activating mutations in East Asians are likely responsible for the greater response to therapy, 27, 28 as the presence of an activating mutation appears to be the over-riding factor when compared with EGFR polymorphism status. For Caucasians, where EGFR mutation and amplification appear to affect a smaller proportion of patients, the attributable role of EGFR polymorphisms may be greater. Our response data analyses suggest that EGFR polymorphisms may offer a partial explanation of the disease stability seen in some individuals treated with EGFR tyrosine kinase inhibition.
Although we found associations between the À216G/T polymorphism and both response rates and toxicity, and differences in PFS for the À216G/T and intron 1 polymorphisms separately, we also found differences in OS when these two polymorphisms were considered together. By considering several different polymorphisms, a more complete picture of polymorphic control of EGFR expression may emerge. Regulation by the intron 1 CA repeat polymorphism is particularly complex, leading some authors to propose that linkage disequilibrium with other promoter polymorphisms may explain the relationship with gene expression. 8 With the current sample size, we could only divide the patients into broad categories by intron 1 allele length, and this may also explain a lack of relationship between this polymorphism and both response rates and treatment toxicity, whereas a strong relationship was found with the À216G/T polymorphism.
In our data set, we found that never-smoker status, nonsquamous histology, and, in particular, any evidence of bronchiolo-alveolar carcinoma elements, and presence of treatment side effects such as rash or diarrhea were associated with improved PFS and OS. These results corroborate findings in other published studies, and suggest that our sample is similar to other Caucasian populations treated with gefitinib. 2, 23, 24, 29 Although performance status and gender were both significant prognostic factors for OS, we did not find significant differences for PFS, probably related to the baseline distribution of patient characteristics.
We acknowledge several limitations. First, the negative results seen in the Arg497Lys polymorphism may be due to lack of power to detect a difference, where the lower boundary of the CI around the AHR for PFS approached one. Second, in combining the intron 1 and À216G/T polymorphisms, the HI-EGFR group had the larger majority of patients, and it may be interpreted erroneously that a large proportion of patients respond to EGFR tyrosine kinase inhibitors. This is not true clinically. 2, 23 However, identifying patients who are least likely to benefit from EGFR tyrosine kinase inhibitor therapy is as important as those who are likely to benefit. To explore these comparisons further, we also compared the extreme groups (highest and lowest expression by polymorphism combinations) only, which had only 27 (29%) individuals in the highest EGFR group and the same 28 patients in the LO-EGFR group; we still found statistically significant differences in PFS and OS.
EGFR protein expression, as measured by immunohistochemistry, does not correlate well with treatment outcomes. EGFR mRNA expression is difficult to measure in needle biopsies that form the predominant form of biopsy material for Stage IV NSCLC patients. EGFR copy number detection by FISH (amplification) is a potentially powerful technique for predicting response to EGFR tyrosine kinase inhibitors, but requires more prospective testing in the clinical setting.
EGFR polymorphisms may become an important adjunct if they are found to predict independently of EGFR copy number for treatment outcomes. Even if EGFR polymorphisms are found to be highly correlated to EGFR mutation status or copy number as detected by FISH, polymorphic testing can still become a surrogate test for individuals who have inadequate tissue specimens for testing, in addition to providing insight into the mechanisms behind these biological findings.
In summary, we describe a new association between a newly described promoter polymorphism, À216G/T, and both treatment outcomes and treatment-related toxicity in gefitinib-treated NSCLC patients. Also, we confirmed that the association between the intron 1 dinucleotide CA repeat polymorphism and PFS holds true in advanced stage NSCLC patients. When À216G/T and the intron 1 dinucletotide CA repeat are considered together, there is a strong association with both OS and PFS. Future studies should compare the roles of mutation, amplification and polymorphic variants simultaneously.
Materials and methods
Patient population
Patients included in this study were entered into two separate studies at Massachusetts General Hospital: (i) one of several clinical treatment studies of gefitinib (since gefitinib was an investigational drug during the period of interest: December 2000 through February 2003); and (ii) a molecular epidemiologic case-control study of lung cancer, where germline DNA from peripheral blood leukocytes were available for genotyping. The clinical studies involving gefitinib were the Expanded Access Study (n ¼ 83), IN-TACT-2 (n ¼ 5; reference 20 ) , and IDEAL-2 (n ¼ 4; reference 2 ) studies. Clinical and epidemiologic data including detailed smoking, family and past medical history were collected on each patient as part of the molecular epidemiologic study. 30 All patients had histologically confirmed diagnoses of NSCLC of all subtypes. Because the criteria for entry into one of the clinical treatment studies, the Gefitinib Expanded Access Study, was broader than the usual clinical trial, one author (GL), a medical oncologist blinded to polymorphism status, re-evaluated every patient for the stricter criteria for analysis: every patient was determined to have a performance status between 0 and 2 as defined by the ECOG, 31 was clinically staged as unresectable Stage IIIB or Stage IV at the initiation of gefitinib therapy, and had an expected lifespan of at least 12 weeks. Both ever-and neversmokers (defined as smoking fewer than 100 cigarettes in their lifetime) were recruited. The original studies and the current analysis were approved by the institutional review boards of Massachusetts General Hospital/Dana Farber Harvard Cancer Center and Harvard School of Public Health. In addition, a comparison group consisting of non-gefitinib treated patients was also assessed for the same polymorphisms; this group consisted of 128 patients described previously. 32 Outcomes definitions OS and progression free survival (PFS) were determined from the first date of administration of gefitinib. Date of death (event) or date last known alive (for censoring) were used to calculate OS. The date of the first radiologic (or pathologic) test confirming disease progression or recurrence was used to calculate PFS. Deaths without recurrence were treated as events for PFS. The date that a patient was last evaluated radiologically (or pathologically) for cancer follow-up was used for censoring PFS data in individuals who were alive at last evaluation. Outcomes data collected from the study were cross-checked with the following: (i) outpatient and inpatient medical records, including radiologic and pathologic reports; (ii) social security death index, for death determination; (iii) Massachusetts General Hospital and Massachusetts (state-wide) Cancer Registries; (iv) records from primary care physicians, other specialists' offices, and hospices for updated information; and (v) as a last resort, information provided by patients and their families. The Response Evaluation Criteria in Solid Tumors (RECIST) criteria were used. 33 Tumor response was categorized as PD, SD or objective partial tumor responses (or PR; there were no complete responses in this sample) using RECIST criteria. Tumor responses were assessed by computed tomography at 2 months, with confirmatory evaluations to be repeated in responders and in patients with SD at least 4 weeks after the initial determination of response.
DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood leukocytes. Genotyping for the CA dinucleotide repeat length polymorphism, and SNPs including À216G/T, À191C/A and Arg497Lys, were performed using published methods. 8, 15, 34 For the CA dinucleotide repeat length polymorphism, primer sequences were 5 0 -GTT TGA AGA ATT TGA GCC AAC C-3 0 (forward) and 5 0 -TTC TTC TGC ACA CTT GGC AC (reverse). The reverse primer was labeled with HEX fluorochrome at the 5 0 -end. Polymerase chain reaction products ranging from 115 to 131 bp were obtained, corresponding to 14-22 CA repeats. For the À216G/T and À191C/A polymorphisms, primer sequences were 5 0 -CTC CTC CTC CTC TGC TCC TC-3 0 (forward) and 5 0 -GGG GCT AGC TCG GGA CTC-3 0 (reverse). The restriction enzyme BseRI recognizes the variant T allele of À216G/T, which produces 73 and 83 bp fragments. The SacII restriction enzyme recognizes the wild type C allele of À191C/A producing 165 and 32 bp fragments. For the Arg497Lys (G-to-A) polymorphism, primer sequences were 5 0 -GCA TGT CTG TGT CAC CCA AG-3 0 (forward) and 5 0 -TGA CAT TCC GGC AAG AGA C-3 0 (reverse). The restriction enzyme BstN1 recognizes the wildtype G allele, which produces 30 and 50 bp fragments. Ten percent of samples were repeated randomly for each of the four polymorphisms, in addition to repeating all samples failing the first genotyping attempt. Samples producing only uninterpretable results and genotyped at least twice were considered to have failed genotyping.
Statistical analysis
Demographic and clinical information was compared across genotype using FET for categorical variables and KruskalWallis test (for continuous variables) where appropriate. The three SNPs were tested for Hardy-Weinberg equilibrium. The CA dinucleotide repeat polymorphism was divided into two groups by allele length based on published expression experiments. 11, 14 Alleles that carried 16 or fewer CA repeats were considered short (S) alleles, whereas those with 17 or greater were considered to have long (L) alleles. For the three SNPs, the homozygous and heterozygous variants were combined together into one group for all analyses because of the low frequency of homozygous variants in the sample set (10% or lower for each SNP). In addition, we evaluated patients with expected higher versus lower EGFR expression on the basis of polymorphism data. We defined the lower EGFR expression group to be individuals carrying at least one intron 1 L allele and G/G genotype of the À216G/T polymorphism (LO-EGFR). All other individuals (i.e., patients who carried an intron 1 S/S genotype and at least one T allele of À216G/T) were considered to have higher EGFR expression (HI-EGFR). Detection of linkage disequilibrium between two SNPs was based on Lewontin's D 0 in controls. 35 Overall haplotype frequencies for the À191C/A and À216G/T SNPs were generated using the Partition Ligation-Expectation Maximization software program (PL-EM) version 1.0, 36, 37 which has been used in other association studies. 38 Potentially relevant covariates assessed included age (either as a continuous variable or dichotomized at the median), gender, race (Caucasian versus other), smoking status (never, ever), clinical stage (Stage IIIB versus IV), histologic subtype (using indicator variables for bronchioloalveolar carcinoma, squamous carcinoma, adenocarcinoma and other subtypes), performance status (ECOG 0 versus 1-2), number of prior chemotherapy treatments (0 versus one or greater), concurrent chemotherapy (yes/no) and presence of any toxicity, defined as any grade of either rash or diarrhea after gefitinib therapy (yes/no). The relationships between each EGFR polymorphism and either response rates or treatment side effects were evaluated using Kruskal-Wallis or FET and stepdown logistic regression, adjusting for relevant covariates. PFS and OS were estimated using the method of Kaplan-Meier, and associations with genetic polymorphisms were assessed using the log-rank test. Median follow-up time was computed among censored observations only. Cox proportional hazards models were also employed to adjust for relevant prognostic covariates. In both logistic and Cox proportional hazards regression, only variables with significant results in univariate analysis (at the Po0.10 level) were included in multivariate analysis; unstable or highly correlated variables were either removed or substituted in the models. The proportional hazard assumption was tested by log-survival function analysis and found to hold in all variables except for smoking status in PFS; thus, in all PFS models, Cox proportional hazard analyses were stratified by smoking status. Regression estimates of the OR and the HR were reported with a 95% Wald CI. All statistical testing was two-sided and utilized SAS software Version 8 (Cary, NC, USA). Kaplan-Meier curves were produced using S-PLUS 6.2 software. P-values o0.05 were considered statistically significant.
Abbreviations
BAC
Bron chiolo-alveolar carcinoma ECOG Eastern Cooperative Oncology Group PD progressive disease PR partial response SD stable disease
